Biotech Company, Endocyte, Earns 175x Return on Investment

Endocyte will be acquired by Novartis for $2.1 billion in cash. The deal, motivated by Novartis’ desire to acquire Endocyte’s prostrate-cancer treatment, is notable for the amount Endocyte paid for this novel treatment. Per an article in the WSJ:

“It bought an exclusive license in October of 2017 for just $12 million in upfront cash, plus an equity grant and future cash incentive payments.”

incredible investments valuation
Source: Charley Grant | "These Guys Should Start a Hedge Fund" | The Wall Street Journal | 10/18/2018 | Visit